Serum Glutamine Synthetase Has No Value as a Diagnostic Biomarker for Alzheimer's Disease

Yannick Vermeiren, Nathalie Le Bastard, Christopher M. Clark, Sebastiaan Engelborghs, Peter P. De Deyn*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)

Abstract

In order to test whether serum glutamine synthetase (GS) is of potential diagnostic value for Alzheimer's disease (AD), we set up a study to compare serum GS concentrations between AD patients and control subjects. The study population (n = 165) consisted of AD patients (n = 94) and age-matched (n = 41) and age-unmatched (n = 30) control subjects. Serum GS analysis was performed by means of ELISA. No significant differences in serum GS levels were found between the AD group and age-matched controls. Age correlated positively with serum GS concentrations in AD patients and control subjects. This study suggests that serum GS levels have no diagnostic value for AD.

Original languageEnglish
Pages (from-to)1858-1862
Number of pages5
JournalNEUROCHEMICAL RESEARCH
Volume36
Issue number10
DOIs
Publication statusPublished - Oct-2011
Externally publishedYes

Keywords

  • Alzheimer's disease
  • Glutamine synthetase
  • Biomarkers
  • Serum
  • BETA-AMYLOID PEPTIDE
  • CEREBROSPINAL-FLUID
  • METABOLIZING ENZYMES
  • OXIDATIVE STRESS
  • CSF BIOMARKERS
  • BRAIN
  • MARKER
  • NEUROTOXICITY
  • DEMENTIA
  • PLASMA

Cite this